Pulmonx Corporation (LUNG) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals. Financial performance shows improvements in net loss and EBITDA, but cash reserves are declining. The sales force restructuring is positive, yet growth is not expected until late 2026. Cost management is effective, but management's lack of clarity on key metrics raises concerns. Market conditions are favorable, but significant growth drivers like Japan and China are limited. Overall, the outlook is balanced, resulting in a neutral sentiment.
Key Financial Performance
Total worldwide revenue (Q4 2025) $22.6 million, a 5% decrease year-over-year (YoY) from $23.8 million. The decline was attributed to operational and executional challenges in the U.S. sales organization.
Total worldwide revenue (Full Year 2025) $90.5 million, an 8% increase YoY. Growth was driven by international markets, particularly Europe, despite challenges in the U.S. market.
U.S. revenue (Q4 2025) $14.1 million, an 11% decrease YoY from $15.9 million. The decline was due to internal operational challenges, including high turnover in the U.S. sales organization.
U.S. revenue (Full Year 2025) $57 million, a 1% increase YoY. Growth was minimal due to the same operational challenges affecting Q4.
International revenue (Q4 2025) $8.5 million, an 8% increase YoY from $7.9 million. Growth was driven by strong performance in European markets, offset by a lack of sales to the distributor in China.
International revenue (Full Year 2025) $33.5 million, a 23% increase YoY. Growth was driven by European markets, despite challenges in China due to inventory issues and pending registration renewal.
Gross margin (Q4 2025) 77.6%, compared to 74% in Q4 2024. The increase was driven by a lower mix of distributor sales in international markets.
Gross margin (Full Year 2025) 74%, consistent with prior performance.
Total operating expenses (Q4 2025) $27.4 million, an 11% decrease YoY. The reduction was due to cost restructuring initiatives.
Total operating expenses (Full Year 2025) $128.8 million, a 1% increase YoY. The increase was driven by higher R&D expenses, offset by cost controls in other areas.
R&D expenses (Q4 2025) $4.6 million, compared to $4 million in Q4 2024. The increase was due to heightened clinical trial activity.
Sales, general and administrative expenses (Q4 2025) $22.9 million, compared to $27 million in Q4 2024. The decrease was due to cost controls implemented during the quarter.
Net loss (Q4 2025) $10.4 million, compared to $13.2 million in Q4 2024. The improvement was due to reduced operating expenses.
Net loss (Full Year 2025) $54 million, compared to a higher loss in 2024. The improvement was due to cost restructuring and better expense management.
Adjusted EBITDA loss (Q4 2025) $5.5 million, compared to $7.5 million in Q4 2024. The improvement was due to reduced operating expenses.
Adjusted EBITDA loss (Full Year 2025) $30.6 million, reflecting ongoing operational challenges but improved cost management.
Cash, cash equivalents, and marketable securities (End of 2025) $69.8 million, a decrease of $31.7 million from the end of 2024. The decrease was due to cash burn and operational expenses.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
AeriSeal program: A key focus for expanding the market, targeting severe COPD patients with collateral ventilation who are not candidates for Zephyr Valves. The CONVERT II pivotal trial is ongoing, with enrollment expected to complete in 2027. This could grow the total addressable market by an estimated 20% globally.
International revenue: Increased by 23% in 2025, driven by strong performance in European markets. However, sales to the Chinese distributor were minimal due to inventory issues and pending renewal of the Chinese registration certificate, expected in the second half of 2026.
Cost restructuring: Reduced operating expenses by over 10%, balancing expense management with investment in growth initiatives.
Debt refinancing: Closed a $60 million credit facility with a 5-year interest-only structure, extending debt maturity to 2031 and providing access to additional capital.
Sales team realignment: Streamlined U.S. sales team priorities to focus on high-impact mandates, reducing turnover and improving productivity. U.S. sales growth is expected to resume in the second half of 2026.
Refocused commercial strategy: Prioritized clinical and operational excellence, focusing on treating physicians, pulmonary service line administrators, and patient education in established centers to improve efficiency and outcomes.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
U.S. Sales Organization Challenges: The U.S. sales organization faced operational and executional challenges, including being stretched across too many competing initiatives, disruptive changes to Territory Manager roles, and a suboptimal sales incentive structure. These issues led to significant turnover, disrupting customer continuity and account management.
Focus Dilution: The sales team was tasked with managing an overly broad set of initiatives, which diluted operational focus and reduced efficiency. This included multiple new call points and services that did not deliver expected returns.
Turnover in Sales Team: High turnover in the U.S. sales organization disrupted customer relationships and account management, impacting sales performance.
China Market Challenges: Sales to the distributor in China were minimal due to inventory overhang from large orders in early 2025 and delays in renewing the Chinese registration certificate, expected only in the second half of 2026.
Financial Losses: The company reported a net loss of $54 million for 2025, with a significant cash burn of $32 million, though efforts are underway to reduce this to $23 million in 2026.
Clinical Trial Delays: Enrollment in the CONVERT II trial for the AeriSeal system is ongoing, with completion expected only in 2027, delaying potential market expansion.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: Pulmonx expects full year 2026 revenue to be in the range of $90 million to $92 million, with year-over-year growth resuming in both U.S. and international businesses starting in the back half of the year.
Gross Margin Projections: The company anticipates a gross margin of approximately 75% for the full year 2026, with margins trending slightly higher in the first half and lower in the second half due to an increased mix of distributor sales.
Operating Expenses: Full year 2026 operating expenses are expected to fall between $113 million and $115 million, inclusive of $21 million in noncash stock-based compensation expense. Excluding stock-based compensation, this represents a 7% to 9% decrease from 2025.
Cash Burn Reduction: Pulmonx aims to reduce its annual cash burn from $32 million in 2025 to $23 million in 2026, a nearly 30% reduction.
Clinical Trials and Market Expansion: Enrollment in the CONVERT II pivotal trial for the AeriSeal system is expected to be completed in 2027, potentially expanding the total addressable market by an estimated 20% globally.
International Market Outlook: International revenue growth in the first half of 2026 is expected to be negatively impacted by minimal sales to the distributor in China, with growth resuming in the second half of the year.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What percentage of the sales force turned over in Q4, and when did the hiring of new reps start and complete?
A:The turnover occurred across the entire year, not just in Q4, and was approximately half of the sales organization. Hiring began in the middle to back part of the year, and nearly all openings are now filled.
Q:How are you incentivizing the sales force now, and what are the focused sales strategies in the U.S.?
A:The incentives are not fundamentally different but have been redesigned to address issues from last year. Changes include better quota allocation and a return to previously successful elements. The plan is now viewed as reasonable and constructive.
Q:Why wouldn't U.S. growth come back sooner now that the sales force is fully in place?
A:The company is coming off a year of decline, with negative 10% year-over-year growth in Q4. Many sales reps are still coming up to speed, and the average tenure of the sales force is different compared to last year. The back half of the year is projected for growth.
Q:What changes were made to reduce the cost structure by 10%, and what is the fixed vs. variable cost structure now?
A:The 10% reduction came from recurring costs, primarily in G&A and marketing, while continuing to invest in sales and R&D. The guide provided reflects a 7%-9% reduction. The fixed vs. variable cost structure was not detailed, but the company is positioned for operating leverage.
Q:How will the company balance investments in the CONVERT II trial with U.S. sales organization investments and cash runway?
A:The company optimized clinical alignment and brought in experienced personnel for the CONVERT II trial. The trial's burn rate is not significant and will not impact spending on commercial operations.
Q:What are the company's longer-term growth aspirations?
A:The company aims to return to a much better growth profile, with double-digit growth expected by Q4 2026. Specific long-term growth aspirations were not detailed.
Q:Are there any fundamental market challenges or surprises affecting performance?
A:The market is becoming more active, with broader investments in pulmonary care. Macro elements like reimbursement and procedure resources are positive, and increased investment in pulmonary care is seen as beneficial.
Q:What is the status of the LungTraX Detect program?
A:The program is being focused on specific hospital profiles where it is most effective. It is not being deprioritized but is being selectively implemented.
Q:What is the expected ramp time for new U.S. sales reps to reach productivity, and what indicators should be watched?
A:The ramp time is typically 6-9 months, depending on the territory. Revenue performance is the key indicator of productivity.
Q:What is the contribution of Japan to 2026 international sales?
A:Japan is contributing through revenue-generating patients in the post-approval study, but it is not a meaningful growth driver for 2026.
Q:What is the contribution of China to 2026 sales?
A:China sales are expected to resume in the second half of 2026. The first half will see minimal sales, leading to year-over-year declines in H1 and growth in H2.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the fixed vs. variable cost structure and long-term growth aspirations. Additionally, the exact impact of the CONVERT II trial on the cash runway and the specific metrics for monitoring sales rep productivity were not fully clarified.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AeriSeal generator
AeriSeal program
AeriSeal step
AeriSeal system
AeriSeal way
CEO review
CONVERT
COPD education
Conference today
Full CEO
Manager role
Officer Chief
action
activity
administrator
assessment
attention
champion
cost
education effort
enrollment
momentum
opportunity physician
option
patient effort
priority sale
profitability
return
sale set
service line
spending
step market
structure
therapy
today Pulmonx
treating
trial step
valve
ventilation
LUNG Transcript
Pulmonx Corporation (LUNG) Q4 2025 Earnings Call Transcript
Unknown3-4
The earnings call presents mixed signals. Financial performance shows improvements in net loss and EBITDA, but cash reserves are declining. The sales force restructuring is positive, yet growth is not expected until late 2026. Cost management is effective, but management's lack of clarity on key metrics raises concerns. Market conditions are favorable, but significant growth drivers like Japan and China are limited. Overall, the outlook is balanced, resulting in a neutral sentiment.
Pulmonx Corporation (LUNG) Q3 2025 Earnings Call Transcript
Unknown11-12
The earnings call reveals mixed financial results with modest revenue growth and increased expenses, particularly in R&D. The guidance revision downward and management's inability to provide clear answers during the Q&A suggest challenges in execution and strategic direction. While international growth and gross margin improvements are positives, the lack of clarity on U.S. growth and strategic pathways, along with cash burn, contribute to a negative sentiment. The market is likely to react negatively to these uncertainties, resulting in a potential stock price decline of -2% to -8%.
Pulmonx Corporation (LUNG) Q2 2025 Earnings Call Transcript
Unknown7-30
The earnings call presents a mixed picture: international revenue growth is strong, but U.S. growth is lagging, and gross margins have declined. The reaffirmed guidance and cash flow breakeven target are positive, but the Q&A reveals uncertainties in U.S. growth and StratX trends. The flat Q3 outlook and cautious guidance for the second half, along with increased expenses, suggest a balanced sentiment. Without a market cap, the stock's reaction is uncertain, but the overall sentiment appears neutral, with no strong catalysts for significant movement in either direction.
Pulmonx Corporation (NASDAQ:LUNG) Q1 2025 Earnings Call Transcript
Unknown5-6
The earnings call presented mixed signals. Financial performance showed growth in sales but a slight decline in gross margin and increased net loss. Guidance was reiterated, with potential upside from U.S. initiatives. Regulatory issues and competitive pressures pose risks, while no shareholder return plans were announced. The Q&A highlighted management's confidence in future growth but lacked specifics on key metrics. Overall, the absence of strong positive catalysts or severe negatives suggests a neutral sentiment.
LUNG Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
